Novavax, Inc. (NVAX)

NASDAQ: NVAX · Real-Time Price · USD

11.19

+1.66 (17.42%)

At close: Feb 26, 2026, 4:00 PM EST

11.09

-0.10 (-0.89%)

After-hours: Feb 26, 2026, 7:59 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development of Recombinant Vaccines		682.16M	983.71M	1.98B	1.15B	475.60M
Development of Recombinant Vaccines Growth		-30.65%	-50.36%	72.89%	141.02%	2448.48%
Total		682.16M	983.71M	1.98B	1.15B	475.60M
Total Growth		-30.65%	-50.36%	72.89%	141.02%	2448.48%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Europe		93.27M	268.36M	-	-	-
Europe Growth		-65.24%	-	-	-	-
Rest of The World		31.92M	233.07M	-	-	-
Rest of The World Growth		-86.30%	-	-	-	-
North America		65.02M	29.96M	-	-	-
North America Growth		117.04%	-	-	-	-
Total		190.21M	531.39M	-	-	-
Total Growth		-64.20%	-	-	-	-

Source: S&P Global Market Intelligence.